<?xml version="1.0" encoding="UTF-8"?>
<p>The use of ISCOM containing influenza viral proteins has been reported to enhance the CD8+ immune responses in mice and humans.
 <xref rid="irv12697-bib-0094" ref-type="ref">94</xref>, 
 <xref rid="irv12697-bib-0095" ref-type="ref">95</xref> Matrix M is a third generation ISCOM and was successfully used as an adjuvant for a H7N9 VLP vaccine in a phase II clinical trial, where the adjuvanted VLP vaccine showed significantly higher seroconversion rates after vaccination compared to non‐adjuvanted VLP vaccine.
 <xref rid="irv12697-bib-0047" ref-type="ref">47</xref>, 
 <xref rid="irv12697-bib-0096" ref-type="ref">96</xref> Also, in a phase I clinical trial involving 60 healthy adults, it was demonstrated that a Matrix M‐adjuvanted H5N1 (NIBRG‐14) vaccine has an acceptable safety profile, capacity for antigen dose sparing and it induced a balanced Th1/Th2 antibody and cellular responses, including multifunctional T cells.
 <xref rid="irv12697-bib-0097" ref-type="ref">97</xref> Furthermore, this vaccine elicited protection against highly pathogenic avian influenza A (H5N1) virus challenge in pre‐clinical murine studies.
 <xref rid="irv12697-bib-0098" ref-type="ref">98</xref>, 
 <xref rid="irv12697-bib-0099" ref-type="ref">99</xref>
</p>
